759 related articles for article (PubMed ID: 28359566)
1. Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment.
Shen Y; Wang H; Sun Q; Yao H; Keegan AP; Mullan M; Wilson J; Lista S; Leyhe T; Laske C; Rujescu D; Levey A; Wallin A; Blennow K; Li R; Hampel H
Biol Psychiatry; 2018 Mar; 83(5):447-455. PubMed ID: 28359566
[TBL] [Abstract][Full Text] [Related]
2. Serum beta-secretase 1 (BACE1) activity increases in patients with mild cognitive impairment.
Zuliani G; Trentini A; Brombo G; Rosta V; Guasti P; Romagnoli T; Polastri M; Marabini L; Pedrini D; Pistolesi C; Pacifico S; Guerrini R; Seripa D; Cervellati C
J Neurochem; 2021 Nov; 159(3):629-637. PubMed ID: 34534363
[TBL] [Abstract][Full Text] [Related]
3. BACE1 and Other Alzheimer's-Related Biomarkers in Cerebrospinal Fluid and Plasma Distinguish Alzheimer's Disease Patients from Cognitively-Impaired Neurosyphilis Patients.
Zhang M; Zhong X; Shi H; Vanmechelen E; De Vos A; Liu S; Chen B; Mai N; Peng Q; Chen X; Wu Z; Hou L; Zhou H; Ouyang C; Zhang W; Liang W; Dai C; Ning Y
J Alzheimers Dis; 2020; 77(1):313-322. PubMed ID: 32804135
[TBL] [Abstract][Full Text] [Related]
4. Processing of the platelet amyloid precursor protein in the mild cognitive impairment (MCI).
Bermejo-Bescós P; Martín-Aragón S; Jiménez-Aliaga K; Benedí J; Felici E; Gil P; Ribera JM; Villar AM
Neurochem Res; 2013 Jul; 38(7):1415-23. PubMed ID: 23575575
[TBL] [Abstract][Full Text] [Related]
5. Characterization of plasma β-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease.
Wu G; Sankaranarayanan S; Wong J; Tugusheva K; Michener MS; Shi X; Cook JJ; Simon AJ; Savage MJ
J Neurosci Res; 2012 Dec; 90(12):2247-58. PubMed ID: 22987781
[TBL] [Abstract][Full Text] [Related]
6. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment.
Zhong Z; Ewers M; Teipel S; Bürger K; Wallin A; Blennow K; He P; McAllister C; Hampel H; Shen Y
Arch Gen Psychiatry; 2007 Jun; 64(6):718-26. PubMed ID: 17548753
[TBL] [Abstract][Full Text] [Related]
7. The feasibility of utilizing plasma MiRNA107 and BACE1 messenger RNA gene expression for clinical diagnosis of amnestic mild cognitive impairment.
Wang T; Chen K; Li H; Dong S; Su N; Liu Y; Cheng Y; Dai J; Yang C; Xiao S
J Clin Psychiatry; 2015 Feb; 76(2):135-41. PubMed ID: 25742200
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal Fluid BACE1 Activity and sAβPPβ as Biomarker Candidates of Alzheimer's Disease.
Alexopoulos P; Thierjung N; Grimmer T; Ortner M; Economou P; Assimakopoulos K; Gourzis P; Politis A; Perneczky R;
Dement Geriatr Cogn Disord; 2018; 45(3-4):152-161. PubMed ID: 29788013
[TBL] [Abstract][Full Text] [Related]
9. Platelet Membrane β-Secretase Activity in Mild Cognitive Impairment and Conversion to Dementia: a Longitudinal Study.
McGuinness B; Fuchs M; Barrett SL; Passmore AP; Johnston JA
J Alzheimers Dis; 2016; 49(4):1095-103. PubMed ID: 26639974
[TBL] [Abstract][Full Text] [Related]
10. Bilateral Hippocampal Volume Mediated the Relationship Between Plasma BACE1 Concentration and Memory Function in the Early Stage of Alzheimer's Disease: A Cross-Sectional Study.
Yin W; Wan K; Zhu W; Zhou X; Tang Y; Zheng W; Cao J; Song Y; Zhao H; Zhu X; Sun Z
J Alzheimers Dis; 2023; 92(3):1001-1013. PubMed ID: 36847009
[TBL] [Abstract][Full Text] [Related]
11. The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease.
De Vos A; Struyfs H; Jacobs D; Fransen E; Klewansky T; De Roeck E; Robberecht C; Van Broeckhoven C; Duyckaerts C; Engelborghs S; Vanmechelen E
J Alzheimers Dis; 2016 Jul; 53(4):1523-38. PubMed ID: 27392859
[TBL] [Abstract][Full Text] [Related]
12. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease.
Zetterberg H; Andreasson U; Hansson O; Wu G; Sankaranarayanan S; Andersson ME; Buchhave P; Londos E; Umek RM; Minthon L; Simon AJ; Blennow K
Arch Neurol; 2008 Aug; 65(8):1102-7. PubMed ID: 18695061
[TBL] [Abstract][Full Text] [Related]
13. Increased Serum Beta-Secretase 1 Activity is an Early Marker of Alzheimer's Disease.
Nicsanu R; Cervellati C; Benussi L; Squitti R; Zanardini R; Rosta V; Trentini A; Ferrari C; Saraceno C; Longobardi A; Bellini S; Binetti G; Zanetti O; Zuliani G; Ghidoni R
J Alzheimers Dis; 2022; 87(1):433-441. PubMed ID: 35275540
[TBL] [Abstract][Full Text] [Related]
14. CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease.
Mouton-Liger F; Dumurgier J; Cognat E; Hourregue C; Zetterberg H; Vanderstichele H; Vanmechelen E; Bouaziz-Amar E; Blennow K; Hugon J; Paquet C
Alzheimers Res Ther; 2020 Jul; 12(1):88. PubMed ID: 32690068
[TBL] [Abstract][Full Text] [Related]
15. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
[TBL] [Abstract][Full Text] [Related]
16. Multiomics Blood-Based Biomarkers Predict Alzheimer's Predementia with High Specificity in a Multicentric Cohort Study.
Souchet B; Michaïl A; Heuillet M; Dupuy-Gayral A; Haudebourg E; Pech C; Berthemy AA; Autelitano F; Billoir B; Domoto-Reilly K; Fowler C; Grabowski T; Jayadev S; Masters CL; Braudeau J
J Prev Alzheimers Dis; 2024; 11(3):567-581. PubMed ID: 38706273
[TBL] [Abstract][Full Text] [Related]
17. Plasma Transthyretin as a Predictor of Amnestic Mild Cognitive Impairment Conversion to Dementia.
Tien YT; Lee WJ; Liao YC; Wang WF; Jhang KM; Wang SJ; Fuh JL
Sci Rep; 2019 Dec; 9(1):18691. PubMed ID: 31822765
[TBL] [Abstract][Full Text] [Related]
18. Increased prediction value of biomarker combinations for the conversion of mild cognitive impairment to Alzheimer's dementia.
Zhao A; Li Y; Yan Y; Qiu Y; Li B; Xu W; Wang Y; Liu J; Deng Y
Transl Neurodegener; 2020 Aug; 9(1):30. PubMed ID: 32741361
[TBL] [Abstract][Full Text] [Related]
19. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
